Asset
DENIFANSTAT
Sagimet Biosciences Inc. Series A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02223247 | phase1 | completed | 2013-11-01 | 2017-06-01 | Sagimet Biosciences Inc. | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors |
| NCT05835180 | phase1 | completed | 2023-05-01 | 2023-12-18 | Sagimet Biosciences Inc. | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function |
| NCT03938246 | phase2 | completed | 2019-03-22 | 2021-10-02 | Sagimet Biosciences Inc. | Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) |
| NCT04906421 | phase2 | completed | 2021-08-12 | 2023-10-02 | Sagimet Biosciences Inc. | Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) |
FDA applications (0)
This company has no applications containing this asset.